Compare
Mineralys Therapeutics, Inc. vs Protagonist Therapeutics, Inc vs Amarin Corp PLC vs Immunome Inc.
| Latest fiscal year | Mineralys Therapeutics, Inc. MLYS | Protagonist Therapeutics, Inc PTGX | Amarin Corp PLC AMRN | Immunome Inc. IMNM |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $46.02M | $213.65M | $6.94M |
| Revenue growth (YoY) | n/a | -89.4% | -6.5% | -23.2% |
| Gross margin | n/a | n/a | 56.6% | n/a |
| Operating margin | n/a | -343.6% | -23.5% | n/m |
| Net margin | n/a | -282.8% | -18.2% | n/m |
| Net income | -$154.65M | -$130.15M | -$38.80M | -$212.39M |
| EPS (Diluted) | -$2.29 | -$2.05 | -$0.09 | -$2.43 |
| Operating cash flow | -$142.42M | $57.67M | $6.73M | -$190.92M |
| Free cash flow | -$142.43M | $56.08M | n/a | -$200.60M |
| Cash & equivalents | $172.92M | $128.39M | $134.66M | $653.48M |
| Total assets | $661.81M | $668.19M | $670.77M | $683.19M |
| Total liabilities | n/a | $53.48M | $211.49M | $48.84M |
| Shareholders' equity | $646.69M | $614.71M | $459.28M | $634.34M |
| Return on year-end equity | -23.9% | -21.2% | -8.4% | -33.5% |
| Shares outstanding | 81.54M | 62.58M | 416.21M | 113.13M |
Revenue, most recent five fiscal years
| Fiscal year | Mineralys Therapeutics, Inc. | Protagonist Therapeutics, Inc | Amarin Corp PLC | Immunome Inc. |
|---|---|---|---|---|
| Latest | n/a | $46.02M Ended 2025-12-31 | $213.65M Ended 2025-12-31 | $6.94M Ended 2025-12-31 |
| 1 year earlier | n/a | $434.43M Ended 2024-12-31 | $228.61M Ended 2024-12-31 | $9.04M Ended 2024-12-31 |
| 2 years earlier | n/a | $60.00M Ended 2023-12-31 | $306.91M Ended 2023-12-31 | $14.02M Ended 2023-12-31 |
| 3 years earlier | n/a | $26.58M Ended 2022-12-31 | $369.19M Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | $27.36M Ended 2021-12-31 | $583.19M Ended 2021-12-31 | n/a |